Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Colorectal Neoplasms 3Sarcoma 2Carcinoma, Renal Cell 2Prostatic Neoplasms 1Lymphatic Metastasis 1Ependymoma 1Colonic Neoplasms 1Clear-cell metastatic renal cell carcinoma 1Bone Neoplasms 1

Interventions

Specimen Handling 9Nivolumab 9Ipilimumab 7cabozantinib 6CTLA-4 Antigen 6pembrolizumab 5Magnetic Resonance Spectroscopy 5Biopsy 4Axitinib 4lenvatinib 2fludarabine 2Blood Specimen Collection 2tivozanib 1sodium-iodide symporter 1sitravatinib 1belzutifan 1aldesleukin 1Zoledronic Acid 1Tissue Banks 1Selenomethionine 1Radiotherapy 1Radiopharmaceuticals 1Pluvicto 1Nephrectomy 1Metastasectomy 1Inulin 1Immunoglobulin G 1Ibandronic Acid 1Hyaluronoglucosaminidase 1Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Clear-cell metastatic renal cell carcinoma × Metastasectomy × 1 year × Clear all
NCT04370509 2025-11-19

Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery

University of California, San Francisco

Phase 2 Terminated
6 enrolled 11 charts
Genitourinary

Clear-cell metastatic renal cell carcinoma, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡